Isobide

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isobide

What Type of Medicine is Isobide and What is its Composition?

Isobide is a registered trade name for a prescription medication containing the active substance Isosorbide Dinitrate (ISDN). It is classified as a Nitrate Vasodilator, belonging to the pharmacological class of Organic Nitrates and the therapeutic category of antianginal agents.

As a synthetic organic compound, Isosorbide Dinitrate serves as the single active ingredient in Isobide. It is produced in oral solid dosage forms, including standard tablets or specialized extended-release versions. These solid forms are designed for administration by swallowing or, in specific formulations, for sublingual use under the tongue. The mechanism of these compounds involves the release of nitric oxide (NO), a signaling molecule naturally present in the body.

What is the General Purpose of Isosorbide Dinitrate?

The primary purpose of Isobide is to reduce the workload on the heart muscle by inducing vasodilation, which is the widening of the blood vessels. This effect occurs when the Isosorbide Dinitrate compound facilitates the release of Nitric Oxide (NO) into the bloodstream. The medication is used to support cardiovascular function in instances where blood flow is restricted.

The relaxation of the vascular smooth muscle decreases both the resistance the heart must pump against (afterload) and the volume of blood returning to the heart (preload). This dual-action reduction in cardiac effort helps balance the heart's oxygen supply and demand. Due to its role in the long-term management of circulatory conditions that require sustained vasodilation, Isosorbide Dinitrate is recognized as a fundamental medication for cardiovascular health.

Regulatory References

  1. List of Essential Medicines

What side effects are possible with Isobide?

Possible Side Effects and Safety Information

The safety profile for Isobide (Isosorbide Dinitrate) is officially documented by regulatory agencies and is primarily defined by the medicine's vasodilating action. Adverse reactions are grouped by the frequency of their occurrence, consistent with regulatory standards.


Frequency-Classified Adverse Reactions

Frequency Category Representative Adverse Reactions
Very Common Headache
Common Dizziness, Somnolence, Hypotension, Orthostatic hypotension, Tachycardia, Asthenia
Uncommon Flushing, Circulatory collapse, Nausea, Vomiting
Very Rare Stevens-Johnson Syndrome, Exfoliative dermatitis

Official Safety Patterns and Constraints

The most frequently observed adverse reactions, such as headache and low blood pressure (hypotension), are generally more likely to appear at the start of treatment or following a dosage increase. Official safety documentation notes that the incidence of headache often diminishes gradually with continued use.

Safety constraints include a strict contraindication for use with Phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil) due to the risk of severe, potentially life-threatening hypotension. Regulatory labels also document the potential for rare, serious outcomes, including circulatory collapse, Methemoglobinemia, and the paradoxical aggravation of angina pectoris.

Caution is warranted for specific populations, including those with severe hepatic (liver) or renal (kidney) impairment, as noted in the prescribing information. This framework structures the medicine's risk profile by detailing expected outcomes and mandatory use restrictions.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Isosorbide Dinitrate is described in regulatory documents as a severe medical emergency that requires immediate intervention due to the potential for life-threatening physiological consequences.

Officially Documented Overdose Manifestations

Overdose presentations stem from a massive, unregulated amplification of the drug's vasodilatory effect. Officially listed signs include a prompt and severe fall in blood pressure (hypotension), a persistent, severe throbbing headache, fainting (syncope), and dizziness. Gastrointestinal symptoms like nausea and vomiting may also be present. In severe cases, the skin may become cold and cyanotic (bluish-colored), and patients may experience seizures or visual disturbances.

Severe Outcomes and Emergency Action

The primary severe outcome is circulatory collapse resulting from profound hypotension. Additionally, the regulatory profile highlights the risk of methemoglobinemia, a condition where oxygen delivery to the tissues is compromised, which can lead to a fatal outcome.

Emergency medical attention must be sought immediately if any symptoms of overdose are suspected. Management is primarily symptomatic and supportive, often requiring procedures to facilitate venous return, such as the Trendelenburg position (head-low, legs raised), and volume expansion with intravenous fluids. Methylene blue is the documented treatment for methemoglobinemia. Furthermore, official information notes that volume expansion may be hazardous in patients with renal failure and congestive heart failure, requiring specialized monitoring.

Therapeutic Uses of Isobide

Main Uses and Therapeutic Benefits of Isobide

The core therapeutic uses of Isobide (Isosorbide Dinitrate) are to manage symptoms and prevent episodes related to two major cardiovascular conditions.

Isobide is commonly used for the long-term prevention of angina pectoris, which involves symptoms related to physical discomfort like tightness or pressure in the chest caused by coronary artery disease. It is also considered relevant as an adjunctive treatment in conditions characterized by periods of heightened symptoms associated with chronic heart failure. This use may assist with mitigating the frequency of symptomatic flare-ups and is relevant for easing manifestations like shortness of breath and breathing difficulty linked to fluid congestion. The key therapeutic domains where it may be relevant include angina prophylaxis and supportive heart failure symptom relief.

“The medication is relevant in contexts involving heightened systemic burden to help ease the overall symptom load.”

This supportive role contributes to easing the overall symptom load, assisting with maintaining functional stability, and supporting general well-being during symptomatic phases.

Quick Fact: Relief for Cardiac Discomfort Isobide is commonly used to help with symptoms related to recurrent ischemic chest pain and is applied in scenarios where additional management of congestive respiratory discomfort is required.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Rules for Isobide (Isosorbide Dinitrate)

The ability to use Isobide is strictly governed by regulatory documentation detailing specific contraindications and population restrictions.

Absolute Contraindications

Use of Isobide is prohibited for patients with a known hypersensitivity to any organic nitrate (including isosorbide dinitrate) or other components of the formulation. It must not be used concurrently with Phosphodiesterase Type 5 (PDE-5) Inhibitors (e.g., sildenafil) or the soluble guanylate cyclase stimulator riociguat, due to the risk of severe hypotension. Furthermore, Isobide is contraindicated in patients with specific cardiovascular conditions, including Hypertrophic Obstructive Cardiomyopathy and severe aortic or mitral stenosis, as well as in cases of marked anaemia.

Population Restrictions

Population Group Regulatory Status
Pediatric Patients Use is not established and not recommended due to lack of safety and efficacy data.
Pregnancy/Lactation Not recommended unless the benefit clearly outweighs the potential risk. Caution is advised during breastfeeding.
Severe Organ Impairment Use with caution is advised for patients with severe hepatic or renal disease.
Older Adults No routine dosage adjustment is needed, but special care is recommended due to potential susceptibility to hypotension.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Isobide (Isosorbide Dinitrate) is defined primarily by the risk of severe pharmacodynamic reinforcement of its potent vasodilatory effects. The co-administration of certain medicines is strictly prohibited due to the potential for life-threatening hypotension.

Absolute Contraindicated Combinations

Interacting Substance Class Regulatory Restriction
PDE5 Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) Co-administration is contraindicated due to risk of profound hypotension and cardiovascular collapse.
sGC Stimulators (e.g., Riociguat) Co-administration is contraindicated due to the risk of severe hypotension.

Furthermore, the drug's effect may be additive when combined with other blood pressure-lowering medicines, including antihypertensive agents (such as beta-blockers and calcium channel blockers), other vasodilators, and Phenothiazines. The consumption of alcohol is also documented to have additive vasodilating effects, which may enhance the hypotensive activity.

Certain interactions necessitate specific spacing rules. For example, due to the critical risk of hypotension, administration of Isobide must be separated by at least 24 hours after the last dose of Vardenafil and at least 48 hours after the last dose of Tadalafil. The regulatory profile also notes the potential for pharmacokinetic modification, stating that strong inhibitors or inducers of the CYP3A4 enzyme may alter the plasma exposure of Isosorbide Dinitrate.

Mechanism of Action

Molecular Bioactivation and NO-cGMP Signaling

Isobide's action is defined by its capacity to modulate vascular tone through activation of the endogenous nitric oxide signaling pathway. The drug functions as a prodrug that is activated by the Mitochondrial Aldehyde Dehydrogenase 2 (ALDH-2) enzyme, which releases the active molecule, Nitric Oxide (NO). This NO then activates the enzyme Soluble Guanylyl Cyclase (sGC) in the vessel walls, leading to a rise in the second messenger, cyclic Guanosine Monophosphate (cGMP). The cGMP cascade promotes the dephosphorylation of smooth muscle proteins, leading to the widening and relaxation of the blood vessels.

Modulation of Systemic Hemodynamics

The relaxation of the vascular smooth muscle results in vasodilation, which primarily affects the veins, significantly increasing their capacity (Venous Capacitance). This action decreases the volume and pressure of blood returning to the heart (Preload). Less dramatically, the reduction in resistance in the arterial system decreases the pressure the heart pumps against (Afterload). This dual hemodynamic adjustment contributes to a reduction in Myocardial Oxygen Demand, affecting the heart’s oxygen supply-demand balance.

Mechanism Limitations: Nitrate Tolerance

The mechanism's reliance on the ALDH-2 enzyme introduces nitrate tolerance, where continuous drug exposure can impair the enzyme's ability to release sufficient NO. Furthermore, the body’s own compensatory mechanisms can work against the drug's effect by activating systems that promote vasoconstriction, thereby reducing the physiological impact of the vasodilation.

Dosage and Administration Information

How to Use Isobide (Isosorbide Dinitrate)

The standard administration of Isobide follows established protocols regarding route, frequency, and dosage. The medicine is primarily available in oral (swallowed) and sublingual (dissolved under the tongue) forms, with intravenous use reserved for acute, specialized settings.

Oral Administration Schedules

Regimen Type Initial Dose Maintenance Range Frequency Constraint
Immediate-Release 5 mg to 20 mg 10 mg to 40 mg Two to three times daily
Extended-Release 40 mg 40 mg to 160 mg Once or twice daily

For chronic use, the dosing schedule incorporates a daily dose-free interval of at least 14 hours. This measure is intended to preserve the drug's long-term efficacy by preventing the development of pharmacological tolerance.

Sublingual Use for Acute Episodes

For the immediate management of symptoms or as prophylaxis before physical activity, the sublingual route is utilized. The typical dose is 2.5 mg to 5 mg. For acute episodes, this dose may be repeated every 5 to 10 minutes, but administration is not to exceed three doses within 15 to 30 minutes. Sublingual tablets are to be placed under the tongue and allowed to fully dissolve; they must not be swallowed or chewed. The immediate-release oral tablets are also preferably taken on an empty stomach.

Population and Form Constraints

The safety and efficacy of Isosorbide Dinitrate have not been established in the pediatric population. Regarding specific tablet forms, extended-release tablets or capsules must be swallowed whole and should never be crushed, chewed, or split, as this alters the drug’s intended release profile.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Isobide

The research on Isobide (Isosorbide Dinitrate) is primarily drawn from controlled clinical trials and large reviews, as documented in official regulatory and scientific sources. The existing evidence base outlines the research conducted regarding its role in two main areas of heart health.


Evidence for Isobide in Angina Pectoris Prevention

The use of Isobide for prevention of stable angina was studied primarily in multiple short-term randomized controlled trials (RCTs). The research primarily examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level in patients with coronary artery disease.

Findings describe patterns observed in the studies related to outcomes related to physical discomfort and exercise capacity compared to placebo. Research describes patterns related to a change in measured response when the medication was observed in continuous administration, a finding known as nitrate tolerance. Research explored specific intermittent dosing schedules; findings indicate that these regimens were associated with maintaining the measured response in the studies. Evidence is limited for outcomes related to long-term quality of life.


Evidence for Isobide as Adjunctive Treatment for Chronic Heart Failure

Research on Isobide's role in chronic heart failure (HFrEF) mostly comes from large-scale randomized controlled trials. Isobide was evaluated in combination with other foundational treatments. The research examined outcomes reflecting major clinical events, such as all-cause mortality, cardiovascular death, and the rate of hospitalization.

Large controlled trials monitored outcomes reflecting all-cause mortality and hospitalization rates in specific cohorts (e.g., African-American patients) when the fixed-dose combination with hydralazine was observed in combination with foundational therapy. When examining long-term outcomes for Isobide alone, some systematic reviews reported that findings were mixed or showed inconsistent results regarding long-term survival or functional capacity. The primary limitation is that most major trials evaluated Isobide only as part of a fixed-dose combination, making it challenging to describe the contribution of Isobide alone.


What Remains Uncertain or Undocumented in the Research

Regulatory sources note that the evidence for the benefits of oral immediate-release Isobide in patients experiencing an acute heart attack or acute congestive heart failure is not fully established, and these remain areas where data are still emerging. Furthermore, appropriate studies on the relationship of age to the effects of Isobide in the pediatric population have not been performed, meaning data for certain groups remain insufficient.

Key Studies & References

  1. Isosorbide Dinitrate Drug Information
  2. List of Essential Medicines (Isosorbide Dinitrate)

Frequently Asked Questions (FAQ)

Common questions about Isobide (FAQ)

Q: How quickly does Isobide start working after taking it?

A: How fast Isobide begins to work depends on the form taken. The sublingual form (dissolved under the tongue) is designed to be absorbed quickly and is used for the immediate management of symptoms. The standard immediate-release oral tablets are not intended to act quickly enough to stop an acute episode of chest discomfort.

Q: How long does the effect of Isobide usually last?

A: The length of time the medicine works varies by formulation. Extended-release forms are designed to provide a sustained effect, often lasting 8 to 10 hours or more. The effect of the sublingual form is intended to be shorter and is used for acute, temporary management.

Q: What is the maximum amount of time Isobide is typically prescribed for?

A: Isobide and similar medicines are generally prescribed for the long-term management of chronic heart conditions, potentially for an extended period. Official product information does not specify a maximum time limit for how long a person can be treated with Isobide.

Q: What is the connection between Isobide and something called 'tolerance'?

A: Tolerance is when the body may get used to the medicine over time, which could potentially reduce its ability to work effectively. Following a dosing schedule that includes a daily drug-free period is described as the protocol used to help maintain the desired effect.

Q: What is the difference between immediate-release and extended-release forms of Isobide?

A: The main difference is the rate at which the medicine is released into the body. The immediate-release form releases the full dose quickly, requiring it to be taken multiple times a day. The extended-release form releases the medicine gradually over many hours, which is associated with less frequent dosing.

Q: Can Isobide be crushed or chewed?

A: Official administration instructions specify that extended-release forms must not be crushed or chewed as this changes how the medicine is designed to be released. The sublingual tablets must be allowed to fully dissolve under the tongue and must not be chewed or swallowed. The standard immediate-release tablet is typically swallowed whole.

Q: Is Isobide for blood pressure or for the heart?

A: Isobide is primarily classified as an antianginal agent and a nitrate vasodilator used for heart conditions. It works by widening blood vessels to reduce the heart's workload, and this action naturally results in a lowering of blood pressure.

Q: Is Isobide an opioid or a habit-forming drug?

A: Isobide is classified as an organic nitrate vasodilator, which is a type of heart medicine, and is not an opioid. Official documentation notes that physical dependence has only been demonstrated in workers exposed to extremely high doses; this finding is based on specific industrial exposure settings.

Q: Is it true that Isobide has been studied for conditions other than heart problems?

A: Yes, Isobide has been the subject of research in clinical trials for use in various cardiovascular situations, such as certain conditions related to pulmonary edema and heart surgery. However, its regulatory approval is specifically for angina pectoris and as an adjunctive treatment for chronic heart failure.

Q: What should I know about Isobide and driving?

A: Because Isobide can cause side effects like dizziness or lightheadedness, regulatory information advises that driving or operating complex machinery should be avoided until an individual knows how the medicine affects their alertness and coordination.

Q: What happens if you miss a dose of Isobide?

A: Regulatory protocol suggests that if a regular dose is missed, it is generally taken as soon as remembered. If it is very close to the time for the next scheduled dose, the missed dose is typically skipped, and the regular schedule is continued. Doses should not be doubled.

Q: Can Isobide be taken with food, or should it be on an empty stomach?

A: In general, Isobide tablets and capsules can be taken with or without food. However, official patient information for the immediate-release oral tablets notes that they are preferably taken on an empty stomach.

Q: Do you need to avoid certain foods or drinks while taking Isobide?

A: Official documentation notes that taking sustained-release tablets with a high-fat meal might increase drug absorption. A consultation with a healthcare professional regarding potential dose changes is warranted if an individual starts a low-fat diet.

Q: Is Isobide described as being safe to use long-term?

A: Isobide is a medicine commonly prescribed for the long-term management of heart conditions and is often taken for extended periods. Regulatory sources indicate that effectiveness and side effects are monitored throughout the duration of use.

Q: What are the most common reasons a doctor would prescribe Isobide?

A: Isobide is officially indicated for two main uses: the prevention of angina pectoris (chest pain) caused by coronary artery disease, and as an adjunctive treatment in specific cases of chronic congestive heart failure.

Q: Is Isobide a preventative medicine or a treatment?

A: Isobide is used for both purposes, depending on the condition being addressed. Official indications show it is used for the prevention of angina pectoris and is also used as an adjunctive treatment (or supportive therapy) to manage the symptoms of chronic heart failure.

Q: Do studies suggest Isobide is more effective for certain groups of people?

A: Research examining Isobide in a fixed-dose combination with hydralazine has shown it provided clinical benefits, such as reduced hospitalization, specifically in the African-American population with heart failure.

Q: Why is Isobide sometimes given as a sublingual tablet?

A: The sublingual (under the tongue) form is used because it allows the medicine to be absorbed into the bloodstream faster than the tablet that is swallowed. This rapid absorption makes it suitable for the immediate relief of acute anginal symptoms.

Q: Does Isobide affect sleep or cause insomnia?

A: Official side effect lists note Somnolence (or drowsiness) as a common adverse reaction. Insomnia (difficulty sleeping) is not typically listed as one of the common side effects described in regulatory documents.

Q: Is Isobide an anticoagulant or 'blood thinner'?

A: No, Isobide is classified as an organic nitrate vasodilator, meaning its function is to widen blood vessels. It works differently than medicines that prevent blood clotting, and is not classified as an anticoagulant or 'blood thinner'.

Q: What is the risk of falling or fainting while on Isobide?

A: Isobide can cause hypotension (low blood pressure) which may lead to dizziness or lightheadedness, increasing the risk of syncope (fainting) or falling. Official information describes that rising slowly from sitting or lying down is a measure used to help minimize this risk.

Q: Can Isobide be used by women who are pregnant or breastfeeding?

A: Official information indicates that use during pregnancy is generally not recommended unless the benefit clearly outweighs the potential risks. Caution is advised while breastfeeding because it is not known if the drug is passed into human milk.

Q: Do doctors ever use Isobide in a hospital setting?

A: Yes, Isobide can be used in a hospital setting. The intravenous (IV) form is reserved for acute, specialized settings, and the medicine has been studied for use in critical conditions like unstable angina and acute decompensated heart failure.

Q: Can Isobide cause problems with vision?

A: Some official side effect lists note blurred vision as a reported event. Additionally, very rare ocular (eye) events, such as a type of glaucoma, have been reported in regulatory documents.

Q: Are there any specific laboratory tests required when taking Isobide?

A: Yes, certain laboratory and medical tests are generally recommended when taking this medicine. These may include regular blood pressure monitoring and in some cases, the drug may interfere with tests such as blood cholesterol levels.

Q: How long does Isobide stay in your system?

A: The drug's primary active substance, isosorbide dinitrate, has a short half-life of about one hour. However, it is converted into an active breakdown product, isosorbide mononitrate, which has a longer half-life of about five hours.

Q: Do official patient leaflets mention any specific lifestyle changes while taking Isobide?

A: Yes, patient information often suggests that complementary lifestyle changes may help the medicine work better. These commonly include dietary adjustments, regular exercise, and information regarding limiting or stopping smoking and alcohol consumption.

Q: Is it normal to have mild flushing after taking Isobide?

A: Flushing (reddening of the skin) is an expected effect because the drug causes blood vessels to widen. This is listed as an uncommon side effect in some regulatory documents and is related to the drug's mechanism of action.

Q: Can Isobide be used in emergency situations?

A: The sublingual form is specifically designed for the immediate relief of acute anginal pain and acts quickly in these situations. However, the standard oral tablets are not intended for acute events, and evidence for use in acute heart attacks is not fully established.

Q: What if I take too much Isobide?

A: Taking too much Isobide may lead to signs of severe low blood pressure, such as severe headache, confusion, fainting, or a fast or irregular heartbeat. Regulatory warnings note a risk of circulatory collapse in severe cases.

Q: Does Isobide change heart rate?

A: Yes, Isobide can change heart rate. Tachycardia (a fast heart rate) is listed as a common adverse reaction in regulatory documents, and a slow heart rate may occur in connection with severe drops in blood pressure.

How should Isobide be stored and disposed of?

The official requirements for storing Isosorbide (Isosorbide Dinitrate/Mononitrate) oral solids are defined by regulatory authorities.

Storage Conditions

  • Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F). The product must be kept from freezing.
  • Protection: Keep the container tightly closed and protect the medicine from light and excessive moisture.
  • Child Safety: All medication must be stored out of the reach of children.

Disposal Instructions

Do not keep outdated or unused medicine. Patients must ask a healthcare professional how to dispose of unused product and are encouraged to use community drug take-back programs. The medication must not be flushed down the toilet or sink unless specifically instructed by the labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isobide found in:

A-Z Index: